Treatment intervention with androgen receptor-targeted agents, taxanes, immunotherapy, targeted radiotherapy, and bone-targeted therapy in most cases only marginally improves survival for patients with advanced disease, highlighting a need to further identify mechanisms underlying prostate cancer metastasis, which can then be targeted. This evidence concerns the gene AR and Familial prostate cancer.